CA3210338A1 - Methods of treating and preventing alloantibody driven chronic graft versus host disease - Google Patents

Methods of treating and preventing alloantibody driven chronic graft versus host disease

Info

Publication number
CA3210338A1
CA3210338A1 CA3210338A CA3210338A CA3210338A1 CA 3210338 A1 CA3210338 A1 CA 3210338A1 CA 3210338 A CA3210338 A CA 3210338A CA 3210338 A CA3210338 A CA 3210338A CA 3210338 A1 CA3210338 A1 CA 3210338A1
Authority
CA
Canada
Prior art keywords
substituted
cgvhd
unsubstituted
inhibitor
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3210338A
Other languages
English (en)
French (fr)
Inventor
Bruce R. Blazar
Ryan Flynn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacyclics LLC
University of Minnesota System
Original Assignee
Pharmacyclics LLC
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics LLC, University of Minnesota System filed Critical Pharmacyclics LLC
Publication of CA3210338A1 publication Critical patent/CA3210338A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
CA3210338A 2013-12-02 2014-12-02 Methods of treating and preventing alloantibody driven chronic graft versus host disease Pending CA3210338A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361910944P 2013-12-02 2013-12-02
US61/910,944 2013-12-02
US201461973178P 2014-03-31 2014-03-31
US61/973,178 2014-03-31
CA2932255A CA2932255C (en) 2013-12-02 2014-12-02 Methods of treating and preventing alloantibody driven chronic graft versus host disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2932255A Division CA2932255C (en) 2013-12-02 2014-12-02 Methods of treating and preventing alloantibody driven chronic graft versus host disease

Publications (1)

Publication Number Publication Date
CA3210338A1 true CA3210338A1 (en) 2015-06-11

Family

ID=53270044

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3210338A Pending CA3210338A1 (en) 2013-12-02 2014-12-02 Methods of treating and preventing alloantibody driven chronic graft versus host disease
CA2932255A Active CA2932255C (en) 2013-12-02 2014-12-02 Methods of treating and preventing alloantibody driven chronic graft versus host disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2932255A Active CA2932255C (en) 2013-12-02 2014-12-02 Methods of treating and preventing alloantibody driven chronic graft versus host disease

Country Status (14)

Country Link
US (6) US20150157634A1 (https=)
EP (1) EP3076975A4 (https=)
JP (5) JP2017501140A (https=)
KR (2) KR20230104754A9 (https=)
CN (2) CN105939717B (https=)
AU (4) AU2014360758B2 (https=)
BR (1) BR112016012158A2 (https=)
CA (2) CA3210338A1 (https=)
EA (1) EA201691020A1 (https=)
IL (4) IL315228A (https=)
MX (2) MX389020B (https=)
PH (2) PH12020552048A1 (https=)
TW (3) TW202228700A (https=)
WO (1) WO2015084857A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210033067A (ko) 2012-06-04 2021-03-25 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
JP2016538270A (ja) 2013-10-25 2016-12-08 ファーマサイクリックス エルエルシー 移植片対宿主病を処置し予防する方法
AR102871A1 (es) 2014-12-03 2017-03-29 Pharmacyclics Llc Métodos de tratamiento de fibrosis
EP3868374A3 (en) * 2016-03-22 2021-11-10 Mayo Foundation for Medical Education and Research Using fatty acid synthase inhibitors to treat fibrosis
WO2018002958A1 (en) * 2016-06-30 2018-01-04 Sun Pharma Advanced Research Company Limited Novel hydrazide containing compounds as btk inhibitors
WO2018075888A1 (en) * 2016-10-21 2018-04-26 Regents Of The University Of Minnesota Materials and methods for treating or preventing graft-versus-host-disease
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
WO2021038540A1 (en) 2019-08-31 2021-03-04 Sun Pharma Advanced Research Company Limited Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
US12496303B2 (en) 2020-10-19 2025-12-16 Washington University Conditioning agents for use in allogeneic hematopoietic stem cell transplantation
WO2022119931A1 (en) * 2020-12-01 2022-06-09 City Of Hope Prevention and treatment of graft-versus-host disease (gvhd)
WO2022161484A1 (en) * 2021-01-30 2022-08-04 Beigene, Ltd. Methods of treating chronic active antibody-mediated rejection using btk inhibitors
US20240287781A1 (en) 2023-02-28 2024-08-29 Toto Ltd. Wall-mounted flush toilet

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
US20060182723A1 (en) * 2005-01-25 2006-08-17 Spellberg Brad J Methods for treating refractory infections in neutropenic individuals
KR20080098490A (ko) * 2006-01-13 2008-11-10 파마시클릭스, 인코포레이티드 티로신 키나제 억제제 및 이의 용도
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
CA2730930C (en) * 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
US8765754B2 (en) * 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
CA2772204A1 (en) * 2009-08-31 2011-03-03 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
CA3007787C (en) * 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
US20120071497A1 (en) * 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
ES2548414T3 (es) * 2011-07-08 2015-10-16 Novartis Ag Novedosos derivados de pirrolo pirimidina
WO2013155347A1 (en) * 2012-04-11 2013-10-17 Izumi Raquel Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
AU2013266069B2 (en) * 2012-05-25 2018-03-15 Sloan Kettering Institute For Cancer Research Methods for treating GI syndrome and graft versus host disease
CA2898472C (en) * 2013-02-15 2023-03-07 Immunomedics, Inc. Chimeric and humanized anti-histone antibodies
JP2016538270A (ja) * 2013-10-25 2016-12-08 ファーマサイクリックス エルエルシー 移植片対宿主病を処置し予防する方法
IL315294A (en) * 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor

Also Published As

Publication number Publication date
IL292522A (en) 2022-06-01
US20240293409A1 (en) 2024-09-05
US20180078558A1 (en) 2018-03-22
CN110478353B (zh) 2022-12-30
IL245715A0 (en) 2016-07-31
TWI743019B (zh) 2021-10-21
TW202402295A (zh) 2024-01-16
JP2025118595A (ja) 2025-08-13
CN105939717A (zh) 2016-09-14
JP2024072291A (ja) 2024-05-27
TW201605454A (zh) 2016-02-16
TW202228700A (zh) 2022-08-01
IL315228A (en) 2024-10-01
AU2020204276A1 (en) 2020-07-16
KR20230104754A9 (ko) 2024-11-15
MX389020B (es) 2025-03-20
AU2024278490A1 (en) 2025-01-09
EP3076975A1 (en) 2016-10-12
US20250381188A1 (en) 2025-12-18
CA2932255C (en) 2023-10-10
PH12020552048A1 (en) 2022-05-11
MX2016006955A (es) 2016-09-07
WO2015084857A1 (en) 2015-06-11
MX2022000209A (es) 2022-02-03
AU2022203810B2 (en) 2024-10-03
AU2014360758B2 (en) 2020-03-26
US20210177854A1 (en) 2021-06-17
CN105939717B (zh) 2019-09-13
KR20160085817A (ko) 2016-07-18
AU2022203810A1 (en) 2022-06-23
US20230100137A1 (en) 2023-03-30
US20150157634A1 (en) 2015-06-11
EP3076975A4 (en) 2017-05-03
PH12016501051A1 (en) 2016-08-15
JP2023029899A (ja) 2023-03-07
JP2020105181A (ja) 2020-07-09
CA2932255A1 (en) 2015-06-11
AU2014360758A1 (en) 2016-06-16
IL276683A (en) 2020-09-30
KR20230104754A (ko) 2023-07-10
BR112016012158A2 (pt) 2017-09-26
JP2017501140A (ja) 2017-01-12
EA201691020A1 (ru) 2017-01-30
CN110478353A (zh) 2019-11-22

Similar Documents

Publication Publication Date Title
AU2022203810B2 (en) Methods of treating and preventing alloantibody driven chronic graft versus host disease
AU2022202686B2 (en) Methods of treating and preventing graft versus host disease
HK40086449A (en) Methods of treating and preventing graft versus host disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231128

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED

Effective date: 20240830

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241125

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250224

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250224

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250422

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250822

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251112

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251112